<DOC>
	<DOCNO>NCT01804712</DOCNO>
	<brief_summary>There substantial evidence B cell recruit prostate cancer CXCL13 release tumor cell . B cell release lymphotoxin drive malignant cell proliferation NFkB pathway . This pilot trial 18 patient determine whether depletion B cell rituximab result decrease extent B cell infiltration prostatic cancer . The extent infiltration diagnostic biopsy compare prostatectomy sample follow administration 4 weekly dos rituximab .</brief_summary>
	<brief_title>Rituximab Neoadjuvant Therapy Patients With Prostate Cancer Scheduled Undergo Radical Prostatectomy</brief_title>
	<detailed_description>This open label , single institution , pilot study rituximab neoadjuvant therapy patient high risk prostate cancer schedule undergo radical prostatectomy . Prior prostatectomy , patient receive one treatment cycle ( 28 day ) rituximab 375 mg/m2 intravenously weekly . Patients schedule undergo radical prostatectomy within two week complete study treatment . Tissue prostatectomy use immunohistochemistry ( IHC ) stain pharmacodynamic marker .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Ability understand provide write informed consent . Patient EITHER : A Kattan nomogram predict probability disease free 5 year surgery &lt; 60 % , OR A Gleason sum ≥ 8 . Indicated radical prostatectomy . Note : candidate radical prostatectomy still eligible even history deep venous thrombosis , pulmonary embolism , and/or cerebrovascular accident currently require systemic anticoagulation . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( Appendix A ) . Males age ≥ 18 year . Adequate organ function define measure within 21 day study entry : Hematology : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9.0 g/dL White blood cell ( WBC ) count ≥ 3.0 x 109/L Biochemistry : Aspartate aminotransferase/serum glutamicoxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamate pyruvate transaminase ( ALT/SGPT ) ≤ 2 x institution 's upper limit normal ( ULN ) Total bilirubin &lt; 1.5 time ULN Serum creatinine blood urea nitrogen ( BUN ) &lt; 1.5 time ULN Na , K Cl , carbon dioxide ( CO2 ) , Ca , phosphate ( PO4 ) within institutional limit Available prostate biopsy specimen evaluable B lymphocyte count . Received prior treatment prostatic adenocarcinoma include prior surgery ( exclude TURP ) , radiation therapy , chemotherapy . Current past use investigational agent within 4 week study enrollment . Evidence metastatic disease cross sectional image bone scan . History hepatitis B C , hepatitis immunodeficiency virus ( HIV ) , tuberculosis chronic infection type . Positive test result chronic hepatitis B infection ( define positive HBsAg serology ) . Positive test result hepatitis C ( hepatitis C virus [ HCV ] antibody serology test ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Castration-resistant</keyword>
	<keyword>Rituximab</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>Rituxan</keyword>
</DOC>